Select region:

Clinical trials located in

Glasgow

Glasgow city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Glasgow, the largest city in Scotland, boasts a rich history dating back to prehistoric times. Renowned for its Victorian and art nouveau architecture, it was a global hub for shipbuilding and marine engineering. The city is the birthplace of many influential figures, including architect Charles Rennie Mackintosh. Glasgow’s vibrant cultural scene is evident in its numerous museums, galleries, and music venues. It also hosts the prestigious University of Glasgow, founded in 1451, making it one of the oldest universities in the English-speaking world.

  • CT-EU-00112395

    Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    DenmarkFranceGermanyHungaryItalyNetherlandsSpainSwedenUnited Kingdom
  • Exploring the Impact of ATL1102 in Boys with Duchenne Muscular Dystrophy

    This study is designed to test the effectiveness and safety of a new treatment called ATL1102. The trial is specifically for boys aged 10 to <18 who cannot walk (non-ambulatory).

    The study is divided into two main parts. In the first part, participants will be randomly assigned to receive either ATL1102 at doses of 25 mg or 50 mg, or a placebo (a treatment with no active drug), given as a weekly subcutaneous injection. This phase will last for 24 weeks and is double-blind, meaning neither the participants nor the researchers will know who is receiving the actual drug or the placebo.

    Following this, all participants will move into the second part of the study, where they will receive ATL1102 for another 24 weeks. This part is open-label, which means everyone will know they are receiving the active drug.

    The main goal of the study is to see how well ATL1102 can improve upper limb strength, which is crucial for daily activities. This will be measured using the Performance of Upper Limb (PUL) 2.0 score, a tool designed to assess upper limb strength in individuals with DMD.

    BulgariaUnited Kingdom
  • Sparsentan Treatment Study for Children with Kidney Diseases

    We are excited to introduce a clinical trial focused on the study of Sparsentan treatment in children and adolescents with certain types of kidney diseases that lead to protein loss in urine, known as proteinuric glomerular diseases. This includes conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), IgA Vasculitis (IgAV), and Alport Syndrome (AS).

    The main goal of this study is to understand how safe, effective, and tolerable Sparsentan is when given as an oral suspension or tablet. We are particularly interested in seeing how this treatment can change the levels of protein in the urine over a period of 108 weeks.

    This study is designed as a Phase 2, Open-Label, Single-Arm trial, meaning all participants will receive the treatment, and there will not be a comparison group receiving a placebo. We are looking to enroll approximately 67 pediatric subjects, aged 1 year to less than 18 years, who have been diagnosed with one of the specified conditions. The study is divided into three populations based on the specific disease and age groups, with different dosages of Sparsentan being tested across these groups.

    The safety of the participants will be closely monitored throughout the study, with a special focus on any treatment-emergent adverse events, serious adverse events, and any adverse events that may lead to discontinuation of the treatment. Additionally, we will measure the change in the urine protein/creatinine ratio (UP/C) from the start of the study to week 108 to assess the effectiveness of Sparsentan in reducing proteinuria.

    This study represents an important step towards finding a potentially effective treatment for children and adolescents suffering from these challenging kidney diseases. If you or your child are dealing with one of these conditions and are interested in participating, we encourage you to consider this unique opportunity.

    GermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Study on the effectiveness of Givinostat in Non-Walking Duchenne Muscular Dystrophy Patients

    This clinical trial is focused on testing the effectiveness, safety, and how well patients can tolerate a medication called Givinostat for those who have Duchenne Muscular Dystrophy (DMD) and can no longer walk. The study is designed for male pediatric patients aged between 9 to less than 18 years. A total of 138 participants will be involved, and they will be divided into two groups. One group will receive Givinostat, and the other group will receive a placebo, which is a substance with no therapeutic effect, designed to mimic Givinostat. This division will be done randomly and both the patients and the doctors will not know who is receiving the actual medication and who is receiving the placebo, making this a double-blind study.

    The main goal of this study is to see if Givinostat can help reduce muscle decline in patients with DMD who cannot walk, by looking at changes in upper limb function after 18 months of treatment. The safety and tolerability of Givinostat in these patients will also be closely monitored.

    Participants will be involved in the study for about 20 to 21 months, which includes a 4-week screening period to confirm eligibility, 18 months of treatment, and a follow-up period. At the end of the treatment period, all participants, regardless of which group they were in, will have the option to join a long-term safety study where they will receive Givinostat.

    BelgiumFranceGermanyItalyNetherlandsUnited Kingdom
  • Clinical Study on Growth and Health in Children with Achondroplasia

    This is a long-term, multi-center, observational study for children aged 2.5 to <17 years who have been diagnosed with achondroplasia. The main objective of the study is to evaluate various aspects of the condition, including growth, medical complications related to achondroplasia, health-related quality of life, body pain, functional abilities, cognitive functions, and treatments received by the participants. The study will monitor changes in height Z score and upper to lower body segment ratio over a period of up to 2 years. No study medication will be administered to the participants during this observational study.

    FranceGermanyItalyNorwaySpainUnited Kingdom
  • CT-EU-00091315

    Testing infigratinib in children aged 3 to 11 years with achondroplasia

    This study focuses on evaluating the medication Infigratinib in young children aged 3 to 11 diagnosed with Achondroplasia who previously participated in the PROPEL study for at least 6 months. The primary objectives of this study are to assess the safety profile of Infigratinib in this specific age group, evaluate the children’s tolerance to potential side effects, and investigate the therapeutic efficacy of the medication for treating Achondroplasia. During the study, doses of Infigratinib will be incrementally increased to determine the optimal and most effective dosage for the participants.

  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    BelgiumCzechiaFranceGreeceHungaryNetherlandsPolandSpainUnited Kingdom
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Assessing imatinib inhalation therapy for pulmonary arterial hypertension

    This clinical study aims to evaluate the safety and efficacy of an inhaled treatment called imatinib (AV-101) for patients with Pulmonary Arterial Hypertension (PAH). The trial is divided into two parts: Phase 2b and Phase 3. In Phase 2b, researchers will test three doses of AV-101 to identify the optimal dose for Phase 3. They will check this by measuring the resistance of the lung vessels — less resistance means the medicine is working. In the following Phase 3, the primary outcome will be the change in the 6-minute walk distance after 24 weeks of treatment compared to a placebo. Participants must be between 18 and 75 years old, have a diagnosis of PAH, and meet specific criteria regarding their disease severity and concomitant therapy.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing a new inhaled drug for pulmonary arterial hypertension

    This study focuses on the efficiency and safety of a new inhaled drug – MK-5475 – for patients suffering from Pulmonary Arterial Hypertension (PAH). The study is divided into two parts: phase 2 and phase 3. In phase 2, the researchers will compare three different doses of MK-5475 with a placebo over a base period of 12 weeks. The goal is to find out if any of the doses can decrease the patient’s pulmonary vascular resistance (PVR), which is the resistance that the heart must overcome to pump blood through the lungs. In Phase 3 of the study, the best performing dose from Phase 2 will be used to confirm its long-term effectiveness, safety, and tolerability over a 12-week base period with a follow-up period of up to five years. The focus is to see if this dose is better than a placebo in improving the patient’s walking distance over 6 minutes. The study aims at improving the quality of life and physical health of PAH patients with the help of the new drug.

    BelgiumFranceGermanyItalyPolandSwedenUnited Kingdom
  • A comprehensive evaluation of retatrutide in obesity and associated comorbidities

    This study evaluates the effectiveness and safety of a new drug, retatrutide, in individuals with obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea. Lasting about 89 weeks, the trial involves randomized assignment of participants to either receive retatrutide or a placebo. The main goals are to observe changes in body weight, knee pain in osteoarthritis, and sleep apnea severity. The study also examines various secondary outcomes like changes in BMI, waist circumference, and blood pressure. The trial aims to provide new insights into weight management and associated health conditions, offering hope for improved treatments.

    HungaryPolandRomaniaSpainUnited Kingdom
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalSpainSwedenUnited Kingdom
  • Testing inhaled imatinib for pulmonary arterial hypertension

    This study is about a new medicine called imatinib (AV-101) which you breathe in as a dry powder. It’s for people who have a health problem called Pulmonary Arterial Hypertension (PAH) – when blood pressure is too high in the arteries that go from the heart to the lungs. The imatinib study will go through two stages. In the first stage, the researchers will try three different amounts of the medicine to find the best one. It will be based on how much it can reduce the resistance in the blood flow in the lungs. In the second stage, they it will be seen how far patients can walk in 6 minutes after taking the medicine for 24 weeks. The study also uses scoring systems to measure how much risk or symptoms a patient has. A higher score means more risk or symptoms.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Comparing treatments for new Large B-cell lymphoma patients

    The trial aims to analyze and compare two drug treatments for people who have a large B-Cell Lymphoma, a kind of cancer that affects a certain type of white blood cells, and have not yet started their treatment. The first treatment is a combination of glofitamab, polatuzumab vedotin, and other common drugs used for this condition: rituximab, cyclophosphamide, doxorubicin, and prednisone. The second treatment is the same, but doesn’t include the glofitamab. The goal is to understand which treatment is more effective and safer for the patient.

    BelgiumDenmarkFranceGermanyItalyPolandSpainUnited Kingdom
  • Study of trastuzumab deruxtecan in gastric cancer or gastroesophageal junction adenocarcinoma

    The aim of the DESTINY-Gastric04 study is to help cancer patients suffering from certain diseases. These patients have a specific type of stomach cancer or adenocarcinoma of the gastroesophageal junction that has not responded to treatment or has gotten worse after treatment with a medicine called trastuzumab. This study is testing a new drug called trastuzumab deruxtecan, comparing it with a combination of two other drugs – ramucirumab and paclitaxel. A key goal of this study is to determine how long participants will live after starting a new treatment. It will also be observed whether the cancer will shrink or stop growing, how long it will last, what the potential side effects of treatment will be and how the body will respond to the new drug.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom

See more clinical trials in other cities in United Kingdom:

.